FDA Gives Green Signal To Reviva Pharma's Late-Stage Schizophrenia Trial

The FDA has notified Reviva Pharmaceuticals Holdings Inc RVPH that it may proceed with Phase 3 trial of its lead candidate, brilaroxazine, a serotonin and dopamine receptor modulator for schizophrenia.

• The FDA has also signed off an additional Phase 3 trial focused on the long-term safety of brilaroxazine in patients with schizophrenia. 
• Related: Reviva Pharma Stock Trading Higher On Detailed Positive Schizophrenia Study Results.
• Both Phase 3 trials will be initiated simultaneously by the end of January 2022.
• Price Action: RVPH shares are up 16.2% at $3.45 during the premarket session on the last check Monday.